Concord Drugs Limited (BOM:538965)

Concord Drugs Revenue

In the fiscal year ending March 31, 2026, Concord Drugs had annual revenue of 787.71M INR with 74.10% growth. Concord Drugs had revenue of 379.23M in the quarter ending March 31, 2026, with 264.93% growth.

• Revenue: 787.71M
• Revenue Growth: +74.10%
• P/S Ratio: 1.37
• Revenue / Employee: 3.15M
• Employees: 250
• Market Cap: 1.08B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2026	787.71M	335.27M	74.10%
Mar 31, 2025	452.45M	3.20M	0.71%
Mar 31, 2024	449.25M	-71.56M	-13.74%
Mar 31, 2023	520.81M	-69.62M	-11.79%
Mar 31, 2022	590.43M	75.99M	14.77%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

May 27, 2026

Data Sources Report a data error